Dr. Ornstein on Role of IL-2 in Patients With RCC

Moshe Ornstein, MD
Published: Monday, Jul 24, 2017



Moshe Ornstein, MD, staff, Cleveland Clinic, discusses the role of interleukin-2 (IL-2) going forward in patients with renal cell carcinoma (RCC).

In 2017, when there are targeted therapies and immunotherapy agents, the benefit of IL-2 in metastatic RCC is that, for a subset of patients, it is one of the only therapies for which researchers have long-term data and long-term durable complete remissions (CRs).

One of the challenges with high-dose IL-2 is patient selection as it is a fairly toxic regimen with a reasonable mortality and morbidity rate, Ornstein explains. Although it is low, it still must be balanced against the durable CRs. Unfortunately, there no current predictive markers. Therefore, it is up to individual physicians to decide with their patients whether they are best suited to tolerate the toxicity of IL-2.

IL-2 is generally administered to young patients with minimal comorbidities who have clear cell RCC who don’t have metastases in the bone or in the brain, he adds.
 


Moshe Ornstein, MD, staff, Cleveland Clinic, discusses the role of interleukin-2 (IL-2) going forward in patients with renal cell carcinoma (RCC).

In 2017, when there are targeted therapies and immunotherapy agents, the benefit of IL-2 in metastatic RCC is that, for a subset of patients, it is one of the only therapies for which researchers have long-term data and long-term durable complete remissions (CRs).

One of the challenges with high-dose IL-2 is patient selection as it is a fairly toxic regimen with a reasonable mortality and morbidity rate, Ornstein explains. Although it is low, it still must be balanced against the durable CRs. Unfortunately, there no current predictive markers. Therefore, it is up to individual physicians to decide with their patients whether they are best suited to tolerate the toxicity of IL-2.

IL-2 is generally administered to young patients with minimal comorbidities who have clear cell RCC who don’t have metastases in the bone or in the brain, he adds.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x